ArticleTechnology in cancer research & treatment

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer.

Binwei Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.